Patent
The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines. Finally the invention relates to diagnostic tools for the detection of Babesia canis associated nucleic acid sequences, for the detection of Babesia canis associated antigens and for the detection of antibodies against Babesia canis associated antigenic material.
1. An isolated Babesia canis protein, said protein having a molecular weight of 32 kD and comprising the amino acid sequence SEQ ID NO: 4.
2. An antigenic composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.
3. The antigenic composition of claim 2 , further comprising an adjuvant.
4. The antigenic composition of claim 2 , further comprising an additional antigen selected from the group consisting of Ehrlichia canis, Babesia gibsoni, vogeli, rossi, Leishmania donovani -complex, Canine parvovirus, Canine distempervirus, Leptospira interrogans serovar canicola, icterohaemorrhagiae, pomona, grippotyphosa, bratislava , Canine hepatitisvirus, Canine parainfluenzavirus, rabies virus, Hepatozoon canis and Borretia burgdorferi.
5. A vaccine comprising the Babesia canis protein according to claim 1 .
6. A vaccine for combating Babesia canis infections, comprising a protein according to claim 1 and a pharmaceutically acceptable carrier.
7. A vaccine according to claim 6 , further comprising an adjuvant.
8. A vaccine according to claim 6 , further comprising an additional antigen selected from the group consisting of Ehrlichia canis, Babesia gibsoni, vogeli, rossi, Leishmania donovani -complex, Canine parvovirus, Canine distempervirus, Leptospira interrogans serovar canicola, icterohaemorrhagiae, pomona, grippotyphosa, bratislava , Canine hepatitisvirus, Canine parainfluenzavirus, rabies virus, Hepatozoon canis and Borrelia burgdorferi.
9. A method of manufacturing a vaccine, comprising mixing a pharmaceutically acceptable carrier and a protein according to claim 1 .